Long-Term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis with Active Choroidal Neovascularization Managed with Intravitreal Bevacizumab

Chen, San-Ni; Yang, Benjamin Chi-Lan

doi:10.1080/09273948.2019.1588335

Cited by 11 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with Coats disease may develop a range of complicating symptoms as their condition progresses, and some severely ill patients may eventually lose their vision [8]. Therefore, it is important to take active measures in clinical treatment to control the occurrence of retinal detachment and promote the improvement of patients' vision.…”

Section: Discussionmentioning

confidence: 99%

Clinical Study of Intravitreal Injection of Anti-VEGF Drugs Combined with Triamcinolone Acetonide in the Treatment of Coats Disease

Fang²,

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Objective. To investigate the clinical study of intravitreal injection of anti-VEGF drugs combined with intravitreal injection of tretinoin for the treatment of Coats disease. Methods. The medical records of 90 patients (120 eyes) with Coats disease admitted to our hospital from April 2010 to June 2021 were selected as retrospective study subjects and divided into control and treatment groups according to the numerical table method. There were 45 cases and 60 eyes in each group. Among them, intravitreal tretinoin drug was injected into the control group, and anti-VEGF drug was injected into the vitreous sclera of the treatment group on the basis of the control group. Results. Before treatment, the differences in visual acuity changes between the two groups were not statistically significant ( P > 0.05 ). After treatment, the light perception, manipulation, and indexes of both groups were significantly improved, and the treatment group was significantly better than the control group. This difference was statistically significant ( P < 0.05 ) for statistical study comparison. The effective rate of 95.56% in the treatment group was significantly higher than that of 86.67% in the control group, and the complication rate was significantly lower than that of the control group, with statistically significant differences ( P < 0.05 ). Conclusion. Intravitreal injection of anti-VEGF drugs combined with tretinoin injection can significantly improve the clinical efficacy of patients with Coats disease and improve visual acuity and central retinal thickness, which has certain reference value for the clinical treatment of Coats disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Study of Intravitreal Injection of Anti-VEGF Drugs Combined with Triamcinolone Acetonide in the Treatment of Coats Disease

Fang²,

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

“…(Ahnood et al 2017) The current treatment for MFC consists of systemic corticosteroids in the early stage of the disease in order to control the inflammatory component; in the case of active CNV, this treatment can be combined with intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF). (Barth et al, 2008;Parodi et al 2013;Niederer et al 2018;Chen et al 2019) Corticosteroid-sparing immunomodulatory therapy (IMT) is widely used for treating noninfectious uveitis to achieve disease control and minimize corticosteroid-related side-effects. (Jabs et al 2000;Galor et al 2008;Niederer et al 2018;Dick et al 2018;Jabs 2018) Recently, the inflammatory component was proposed to trigger the onset and growth of CNV in MFC, suggesting that IMT such as methotrexate and mycophenolate mofetil may be used as a preventive treatment for MFC.…”

Section: Introductionmentioning

confidence: 99%

The efficacy of corticosteroid‐sparing immunomodulatory therapy in treating patients with central multifocal choroiditis

Groot

Loon

Boer

et al. 2020

Acta Ophthalmologica

View full text Add to dashboard Cite

Purpose To evaluate the efficacy of corticosteroid‐sparing immunomodulatory therapy (IMT) in patients with recurrent and/or sight‐threatening central multifocal choroiditis (MFC). Methods This was a retrospective cohort study in a tertiary uveitis centre including all patients with MFC who have been treated with IMT for at least 12 months. Clinical data and imaging results were collected regarding the period prior to the start of IMT and at 3, 6, 12 and – where available – 24 months after the start of IMT. Main outcome measure was the number of annual recurrences of choroiditis with or without active choroidal neovascularization before and after the start of IMT. Secondary outcomes were the percentage of patients with (steroid‐free) remission and the median time between the start of IMT and (steroid‐free) remission. Results Thirty‐two patients (39 eyes) were included. At the start of IMT, none of the patients were in (steroid‐free) remission. At 24 months, the probability of achieving remission and steroid‐free remission was 88,5% and 50%, respectively. The median time to achieve remission and steroid‐free remission was 21 and 83 weeks, respectively. In 17 patients (20 eyes) with available clinical data and imaging results for ≥ 12 months prior to the start of IMT, the mean number of recurrences/year decreased significantly from 1.40 ± 0.81 at baseline to 0.49 ± 0.47 (p = 0.001) after the start of IMT. Conclusions Preventive therapy with IMT should be considered in patients with recurrent and/or sight‐threatening MFC to decrease the number of recurrences/year and to increase the prospects of achieving either remission or steroid‐free remission.

show abstract

“…1,2,38,39 Antimicrobial therapy should be added in eyes with CNV in the setting of active toxoplasmic or tuberculous retinochoroiditis. Four Original Articles [40][41][42][43] and two Letters 44,45 in this issue of Ocular Immunology & Inflammation (OII) describe the occurrence, clinical and multimodal imaging features, and management of CNV in the setting of uveitis.…”

mentioning

confidence: 99%

“…The authors cited similar, recently reported patients with PIC and FCE who developed secondary CNV in the area of excavation and noted that both their patient and others tended to respond well to a limited number of intravitreal anti-VEGF agent injections. 44 Chen et al 43 retrospectively evaluated the clinical features, treatment and outcome of 23 eyes in 22 consecutive patients with MFC/PIC that developed active CNV treated with anti-VEGF agents (all eyes) and systemic corticosteroids (21 eyes), 0.5 mg/kg tapered over 1-3 months, at a tertiary referral center in Taipei, Taiwan, between January, 2006, and April, 2018. Twenty-one of the subjects (95.5%) were female, with a mean age of 33.2 years (range 14-66 years).…”

mentioning

confidence: 99%

Inflammatory Choroidal Neovascularization

Cunningham

Pichi

Dolz-Marco

et al. 2020

Ocular Immunology and Inflammation

View full text Add to dashboard Cite

Long-Term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis with Active Choroidal Neovascularization Managed with Intravitreal Bevacizumab

Cited by 11 publications

References 20 publications

Clinical Study of Intravitreal Injection of Anti-VEGF Drugs Combined with Triamcinolone Acetonide in the Treatment of Coats Disease

Clinical Study of Intravitreal Injection of Anti-VEGF Drugs Combined with Triamcinolone Acetonide in the Treatment of Coats Disease

The efficacy of corticosteroid‐sparing immunomodulatory therapy in treating patients with central multifocal choroiditis

Inflammatory Choroidal Neovascularization

Contact Info

Product

Resources

About